Marlise R. Luskin

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Marlise R. Luskin

Feb 7, 2025, 08:42 | Science

Shai Shimony: Biology and Management of NPM1 Mutated AML

Shai Shimony, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared an article by Evan C.…

Nov 15, 2024, 13:56 | Insight

Article of the Week, Suggested by the BPDCN International Registry

Immune Oncology Research Institute shared a post on LinkedIn: “Article of the Week Suggested by the BPDCN…

Oct 4, 2024, 15:11 | Blog

Bleeding risk in ET patients with extreme thrombocytosis

Joan How, Hematologist and Chief of Hematology at Brigham and Women's Faulkner Hospital, shared an…

Oct 1, 2024, 11:39 | Blog

Marlise R. Luskin: Severe neutropenia is associated with blinatumomab

Marlise R. Luskin, leukemia specialist at Dana-Farber Cancer Institute, posted on X: "Severe neutropenia is…

Jun 26, 2024, 05:00 | Blog

Lachelle Dawn: Fellows can join the Dana Farber’s division of Leukemia

Lachelle Dawn, Hematologist and Scientist at Dana-Farber Cancer Institute, shared on X: “I work with…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023